Hologic, Inc. (Nasdaq: HOLX) announced that Amy Wendell has been elected to the Company's Board of Directors, effective December 14. Ms. Wendell also was appointed to the Company's Audit and Finance Committee.
Ms. Wendell brings to Hologic a wealth of experience in the healthcare industry, particularly in the areas of market and technology development. As Senior Vice President of Strategy and Business Development for Covidien plc, until it was acquired by Medtronic in 2015, Ms. Wendell led strategic planning and portfolio management, as well as all business development initiatives including mergers and acquisitions, integrations, equity investments, divestitures, licensing, distribution and market intelligence.
"It is a pleasure to welcome Amy to Hologic's Board of Directors," said Steve MacMillan, the Company's Chairman, President and Chief Executive Officer. "Amy's strategic acumen, combined with her depth of experience in operational, product and overall portfolio management, are a great addition to our Board."
Ms. Wendell is also a Director of Ekso Bionics, AxoGen, Inc., and Por Cristo, a non-profit organization. She received a bachelor's degree from Lawrence Technological University (Mich.) and a master's degree in biomedical engineering from the University of Illinois.
Source & Image Credit: Hologic
More About Hologic
